No Benefit to Adding Chemotherapy in Older Adults With NSCLC

Adding chemotherapy to immunotherapy increased the adverse event burden without improving survival outcomes compared with immunotherapy alone in older adults with NSCLC.
Medscape Medical News

source https://www.medscape.com/viewarticle/no-benefit-adding-chemo-immunotherapy-older-adults-nsclc-2024a10004rp?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost